Pre-clinical studies have confirmed that anti-CD47 enhances the anti-tumor efficacy of anti-PD1/PD-L1, including in melanoma, colon carcinoma, lung cancer, and high-Ep-CAM cancer cells [60–62]. This evidence concerns the gene CD47 and cancer.